Abstract
Alpha-cyclodextrin (αCD) is a natural bacterial product that is widely used as a food ingredient. In the EU, αCD is regulated as a “dietary fiber” with an authorized health claim “for contributing to the reduction of postprandial glycemic responses”. In the US, αCD is generally recognized as save (GRAS), but on April 25, 2022, the U.S. Food and Drug Administration (FDA) rejected the inclusion of αCD in the list of “dietary fibers” because “the strength of the scientific evidence does not support a finding of a beneficial effect of αCD on postprandial blood glucose …”.
This meta-analysis reviews clinical trials conducted to test the effect of αCD on blood glucose and insulin levels during three hours after consumption of a meal comprising carbohydrates, fats, and proteins.
Several issues related to the standardization of the outcomes, the choice of the statistical methods in the cross-over studies conducted, and the choice of methods for the aggregation of P-values are discussed. In conclusion, the EU decision is confirmed and extended. The administration of αCD not only reduces the postprandial glycemic responses, but the absence of an increase in insulin levels suggests that αCD acts independent of increasing insulin production and, thus, their beneficial effect is not affected by insulin resistance.
Competing Interest Statement
Author Knut M. Wittkowski is currently the CEO of ASDERA LLC, a company discovering novel pharmacological and nutritional interventions against complex (incl. cardiovascular) diseases from data of genome-wide association studies. The discussion of statistical aspects in the meta-analysis / systematic review in this publication was not affected by any commercial or financial relationships that could be construed as a potential conflict of interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
copyright information added and text revised.
Data Availability
All data used are available online as part of the publications cited.
